Bazarbashi S.; Bachour M.; Bulbul M.; Alotaibi M.; Jaloudi M.; Jaafar H.; Mukherji D.; Farah N.; Alrubai T.; Shamseddine A.
(Elsevier Ireland Ltd; NEW YORK360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA, 2014)
Although most patients with prostate cancer respond to initial androgen-deprivation therapy, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. In 2004, the docetaxel-prednisone regimen was ...